Which statement accurately reflects acute migraine treatment options?

Which statement accurately reflects acute migraine treatment options?

• A. Only opioids are used
• B. Only triptans are used
• C. A combination includes non-opioid analgesics, caffeine, serotonin agonists, CGRP agonists, and ergotamines
• D. Ergotamines alone are sufficient

Answer: (C)

Acute migraine treatment relies on a multi-pronged approach that targets different parts of the pain pathway to achieve rapid relief. Non-opioid analgesics, like NSAIDs, reduce inflammation and pain signaling. When timed with caffeine, these analgesics can work more effectively and may help with absorption. Serotonin receptor agonists (triptans) are a cornerstone for many attacks, causing cranial vasoconstriction and decreasing the release of pain-promoting neuropeptides. Newer CGRP pathway agents—either CGRP receptor antagonists or other modulators that blunt CGRP’s effects—offer another route to prevent or reduce attack intensity by interrupting a key migraine mediator. Ergot derivatives, though older, are still used in some cases for their vasoconstrictive effects, typically when other treatments aren’t suitable or effective. Since migraine management is tailored to the individual, clinicians often combine agents from these classes to optimize relief, reflecting the broad range of options available for acute treatment.

Acute migraine treatment relies on a multi-pronged approach that targets different parts of the pain pathway to achieve rapid relief. Non-opioid analgesics, like NSAIDs, reduce inflammation and pain signaling. When timed with caffeine, these analgesics can work more effectively and may help with absorption. Serotonin receptor agonists (triptans) are a cornerstone for many attacks, causing cranial vasoconstriction and decreasing the release of pain-promoting neuropeptides. Newer CGRP pathway agents—either CGRP receptor antagonists or other modulators that blunt CGRP’s effects—offer another route to prevent or reduce attack intensity by interrupting a key migraine mediator. Ergot derivatives, though older, are still used in some cases for their vasoconstrictive effects, typically when other treatments aren’t suitable or effective. Since migraine management is tailored to the individual, clinicians often combine agents from these classes to optimize relief, reflecting the broad range of options available for acute treatment.